UNSPSC 51181930: Nitromifene citrate

This classification denotes an antiestrogen with the molecular formula C27H28N2O4.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TN5UQ266RA, chemically known as 1-(2-(p-(alpha-(p-methoxyphenyl)-beta-nitrostyryl)phenoxy)ethyl)pyrrolidine, monocitrate but more generally known as nitromifene citrate, which bears US NIH Compound Identifier 3032492. Most nations, for tariff and trade purposes, schedule nitromifene citrate under HS 29339990 and SITC 51577.

As of Q4 2014, NITROMIFENE CITRATE remains US FDA's Preferred Term for this commodity. Nitromifene citrate bears US NLM identifiers UMLS ID C0919387 and NCI Concept Code C90721. SMILES: COC1CCC(CC1)C(=C(C2CCCCC2)[N+](=O)[O-])C3CCC(CC3)OCCN4CCCC4.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51181930 Nitromifene citrate is a Commodity code covering the procurement of this specific contraceptive pharmaceutical product. State and local governments rarely issue direct solicitations for individual drug commodities by NDC or generic name; instead, they source nitromifene citrate and thousands of other pharmaceuticals through multi-source generic drug and over-the-counter (OTC) product cooperative purchasing agreements that bundle broad therapeutic categories and allow authorized wholesalers to fulfill orders from qualified manufacturers. The work involves supplying finished pharmaceutical products—in this case nitromifene citrate in its various formulations and packaging configurations—that meet FDA requirements, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) compliance. Vendors must maintain contractual relationships with authorized wholesalers such as AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and offer flexible pricing structures (flat price, net price, or WAC-minus formats) with detailed product information including NDC codes, SKUs, UPCs, strength, dosage form, and manufacturing locations. The issuing bodies are state governments and their multistate cooperative purchasing alliances, which aggregate demand across state agencies, counties, cities, and other member jurisdictions.

The MMCAP generic multi-source pharmaceuticals RFP (S1070000015802), issued by the Minnesota Department of Administration's Office of State Procurement on January 20, 2026 with responses due March 26, 2026, is the primary recent activity. MMCAP serves Minnesota and Oregon, and the resulting contracts will be effective July 1, 2026, for a two-year term with optional extensions. Evaluation emphasizes price competitiveness (75 percent) and compliance with administrative requirements, including the submission of comprehensive product data in CSV format and agreement to a 3 percent administrative fee on all contract purchases. Vendors must carry workers' compensation insurance and commercial general liability of $5,000,000 per occurrence, and all products must have an expiration date of at least one year from manufacture with a minimum six-month shelf life. Performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials.